TNF and inflammatory bowel disease: However, information on treatment success exists in children for alternative biologicals such as golimumab, certolizumab (both TNF-α inhibitors), vedolizumab, an α4β7-integrin blocker, and ustekinumab, an IL-12/IL-23 blocker (see Figure 1 for an overview of currently used biologicals in pediatric IBD).